The prevalence is estimated to double every two decades, reaching approximately 80 million affected patients worldwide in 2030 ( 1). This report suggests that GSCT is a viable cognitive screening instrument for both MCI and dementia.Äementia is currently a global driver of health care costs, and with an ageing demographic, the disease burden of neurodegenerative disorders will increase exponentially in the future. Overall, MoCA showed a sensitivity of 0.88 and specificity of 0.54 at a cut-off of <=26 while GSCT displayed 0.91 and 0.55 in sensitivity and specificity respectively at a cutoff of <=45. GSCT total test time differed significantly between all diagnostic subgroups (p<0.05). Mean score differed significantly between all diagnostic subgroups for both GSCT and MoCA (p<0.05). Descriptive statistics and specificity, sensitivity and ROC curves were established for both test. All patients were administered both MoCA and GSCT. 66% were diagnosed with subjective cognitive impairment (SCI), 25% with mild cognitive impairment (MCI) and 9% fulfilled criteria for dementia.
![moca electronic cognitive assessment moca electronic cognitive assessment](https://dfzljdn9uc3pi.cloudfront.net/2022/12917/1/fig-2-full.png)
All patients were assessed for presence of neurodegenerative disorder in accordance with standard investigative procedures. Methodsġ06 patients, referred to the memory clinic, Karolinska University Hospital, due to memory complaints were included.
![moca electronic cognitive assessment moca electronic cognitive assessment](https://cdn.cnn.com/cnnnext/dam/assets/180116161808-trump-mental-test-moca-super-tease.jpg)
In this proof of concept report, we examine the validity of a newly developed digital cognitive test, the Geras Solutions Cognitive Test (GCST) and compare its accuracy against the Montreal Cognitive Assessment (MoCA). Due to an ageing demographic and rapid increase of cognitive impairment and dementia, combined with potential disease-modifying drugs and other interventions in the pipeline, there is a need for the development of accurate, accessible and efficient cognitive screening instruments, focused on early-stage detection of neurodegenerative disorders.